Pure Global
NCT05734898

NKG2D CAR-NK & r/rAML

NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Zhejiang University·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
AML
Drug/Device/Intervention
NKG2D CAR-NK
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Zhejiang University
Location
Hangzhou,Hangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2023
End date
Sep 01, 2024
Enrollment
30 participants
Primary outcome

DLT,MTD

Summary

This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment
 of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical
 safety and efficacy.

ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05734898
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05734898 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhejiang University and is currently Recruiting. The study focuses on AML. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.